CK Life Sciences Int'l., (Holdings) Inc.

DB:LSI Stock Report

Market Cap: €517.8m

CK Life Sciences Int'l. (Holdings) Valuation

Is LSI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LSI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LSI (€0.05) is trading below our estimate of fair value (€0.06)

Significantly Below Fair Value: LSI is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LSI?

Key metric: As LSI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LSI. This is calculated by dividing LSI's market cap by their current revenue.
What is LSI's PS Ratio?
PS Ratio0.8x
SalesHK$5.38b
Market CapHK$4.23b

Price to Sales Ratio vs Peers

How does LSI's PS Ratio compare to its peers?

The above table shows the PS ratio for LSI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.6x
FYB Formycon
14x33.4%€848.4m
BIO3 Biotest
1.5x3.6%€1.4b
HPHA Heidelberg Pharma
12x16.6%€102.1m
MDG1 Medigene
3x16.1%€22.5m
LSI CK Life Sciences Int'l. (Holdings)
0.8xn/a€4.2b

Price-To-Sales vs Peers: LSI is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (7.6x).

Price to Sales Ratio vs Industry

How does LSI's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.8.0x21.8%
LSI CK Life Sciences Int'l. (Holdings)
 0.8xn/aUS$543.41m
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
LSI 0.8xIndustry Avg. 8.0xNo. of Companies6PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.8.0x42.4%
LSI CK Life Sciences Int'l. (Holdings)
 0.8xn/aUS$543.41m
No more companies

Price-To-Sales vs Industry: LSI is good value based on its Price-To-Sales Ratio (0.8x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is LSI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LSI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate LSI's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R74.3b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R9.00

7D

0.6%

1Y

5.3%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

7D

0.4%

1Y

-33.2%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.45

7D

1.1%

1Y

2.9%